Evorpacept

N/A

Report date: 2026/04/08 20:02:35

Base Information

Drug NameEvorpacept
Drug Alias NameALX148ALX-148
ClassificationBiologics > Protein drugs > Recombinant protein > Fusion protein > Fc fusion protein
Mechanisms of ActionCluster of differentiation 47 inhibitors
TargetsCluster of differentiation 47
Therapy Area/IndicationsPrimary mediastinal B cell lymphomaMetastatic breast cancerSolid tumours +[24] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryCzechiaBelgiumCanada +[20] 
CombinationsNo
Global Highest StatusPhase 3 Clinical
Highest Status in ChinaN/A
Originator CompaniesAlexo Therapeutics
China Registration ClassN/A

Develop Information

Active CompaniesAlexo TherapeuticsAlx Oncology IncThe University Of Texas MD Anderson Cancer Center +[4] 
Inactive CompaniesN/A
Active IndicationsPrimary mediastinal B cell lymphomaMetastatic breast cancerSolid tumours +[21] 
Inactive IndicationsMyelodysplastic SyndromesLeukemia, Myeloid, AcuteNeoplasms

Other Information

ATC CodeN/A
Related LinksN/A